- Home
- LVLU vs NXTC Comparison
LVLU vs NXTC Comparison
Compare LVLU & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- NXTC
- Stock Information
- Founded
- LVLU 1996
- NXTC 2015
- Country
- LVLU United States
- NXTC United States
- Employees
- LVLU N/A
- NXTC N/A
- Industry
- LVLU Catalog/Specialty Distribution
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- NXTC Health Care
- Exchange
- LVLU Nasdaq
- NXTC Nasdaq
- Market Cap
- LVLU 10.8M
- NXTC 12.8M
- IPO Year
- LVLU 2021
- NXTC 2019
- Fundamental
- Price
- LVLU $3.95
- NXTC $4.85
- Analyst Decision
- LVLU Hold
- NXTC Strong Buy
- Analyst Count
- LVLU 1
- NXTC 2
- Target Price
- LVLU $15.00
- NXTC $25.50
- AVG Volume (30 Days)
- LVLU 40.0K
- NXTC 18.5K
- Earning Date
- LVLU 08-13-2025
- NXTC 11-06-2025
- Dividend Yield
- LVLU N/A
- NXTC N/A
- EPS Growth
- LVLU N/A
- NXTC N/A
- EPS
- LVLU N/A
- NXTC N/A
- Revenue
- LVLU $292,337,000.00
- NXTC N/A
- Revenue This Year
- LVLU N/A
- NXTC N/A
- Revenue Next Year
- LVLU $2.53
- NXTC N/A
- P/E Ratio
- LVLU N/A
- NXTC N/A
- Revenue Growth
- LVLU N/A
- NXTC N/A
- 52 Week Low
- LVLU $2.98
- NXTC $2.69
- 52 Week High
- LVLU $28.05
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- LVLU 47.01
- NXTC 41.16
- Support Level
- LVLU $3.67
- NXTC $4.83
- Resistance Level
- LVLU $4.70
- NXTC $5.15
- Average True Range (ATR)
- LVLU 0.35
- NXTC 0.23
- MACD
- LVLU -0.00
- NXTC -0.02
- Stochastic Oscillator
- LVLU 26.80
- NXTC 7.14
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.